Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Trial of Sleeping Beauty-Modified Third-Generation Anti-CD19 CAR T-Cell Therapy (TCRs) to Treat Solid Tumors

Trial Profile

A Phase 1 Trial of Sleeping Beauty-Modified Third-Generation Anti-CD19 CAR T-Cell Therapy (TCRs) to Treat Solid Tumors

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Aug 2019 According to a ZIOPHARM Oncology media release, this trial is expected to begin in late 2019.
    • 05 Mar 2019 According to a ZIOPHARM Oncology media release, The Company affirms guidance on beginning this trial and treating patients at MD Anderson Cancer Center in the second half of this year.
    • 09 Oct 2018 According to a ZIOPHARM Oncology media release, the company have affirmed its guidance on this planned phase I study.The IND application for this phase 1 trial remains on track to be submitted in the fourth quarter of 2018 followed by enrollment of patients beginning in 2019, pending regulatory clearance.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top